Want to see EVAX full AI Analyst Report?
EVAX Stock Chart & Stats
$4.45
-$0.02(-2.40%)
At close: 4:00 PM EST
$4.45
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$2.45 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)28.81K
Market Cap
$27.11M
Enterprise Value$5.24M
Total Cash (Recent Filing)$18.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding8,340,215
10 Day Avg. Volume20,533
30 Day Avg. Volume28,813
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.48
Forecast
1Y Price Target
$11.25Price Target Upside152.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
Clinically Validated AI PlatformHigh Phase II immunogenicity (86%) and de novo T‑cell responses demonstrate the AI-Immunology platform’s predictive power and clinical translatability. Clinical validation across oncology trials reduces platform technical risk, strengthening licensing and partnership leverage and supporting durable R&D productivity.
Scalability Into Hard-to-treat Tumors (GBM)Demonstrated ability to design personalized vaccines for all 24 GBM cases, including ERV antigens, shows the platform can address low-mutational-burden tumors. This expands the addressable clinical market, improves long-term program breadth, and makes the company a more attractive collaborator for large oncology partners.
Improved Balance Sheet And RunwayEquity turned positive and debt was reduced, with cash providing runway into H2 2027 per management. Stronger capitalization lowers near-term solvency risk and gives the company time to secure partnerships or milestones, enabling strategic deal-making rather than emergency financing in the medium term.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business remains dependent on external financing or partnerships to sustain operations. Even with improved burn, ongoing cash consumption creates dilution and refinancing risk and constrains the company’s ability to self-fund later-stage trials or commercialization efforts.
Small, Volatile Revenue BaseRevenue remains immaterial and volatile, reflecting a transition-stage commercial profile rather than recurring product sales. Without stable, diversified revenue streams, the company’s operating model relies on milestone/collaboration cash flows, increasing funding vulnerability and limiting long-term margin predictability.
Partnerships Not Finalized; Dilution Pathway EnabledManagement reports active BD discussions but no signed partnerships; concurrently shareholders authorized broad equity-linked financing. Absent finalized deals, the firm faces funding uncertainty and an elevated probability of equity/convertible issuance, which can dilute investors and affect strategic optionality over the medium term.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $2.45 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $27.11M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Aug 20, 2026 which is in 40 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on May 07, 2026. The company reported -$0.01 earnings per share for the quarter, the consensus estimate of -$0.01 by $0.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 8,340,215 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of -$0.01 in its last earnings report, expectations of -$0.01. Following the earnings report the stock price went down -7.71%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX Company Deck
EVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong R&D and platform momentum, highlighted by robust EVX-01 immunogenicity (86% immunogenicity and de novo response rates), supportive clinical signals (75% overall response rate previously reported), platform scalability into GBM (fully personalized designs for 24/24 cases, with 21/24 designs including both neoantigen and ERV components), and novel vaccine concepts (polio work with The Gates Foundation). The company also reinforced disciplined financial management and confirmed cash runway into H2 2027. Key risks discussed include a finite cash runway, a Q1 net loss of USD 3.6M and reduced equity, and the absence of finalized partnerships to extend funding or accelerate certain programs. On balance, the positive clinical and platform developments materially outweigh the financial and partnership uncertainties, though the latter remain important near-term considerations.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.25
▲(152.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
2.33% Other Institutional Investors
97.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---